Vasa Therapeutics Announces Closing Of Seed Financing To Advance Novel Therapies For Diseases Of Cardiovascular Aging

Jan 03, 2024•almost 2 years ago

Round Type

seed

EncinitasBiotechnology Research

Investors

Seed FolioNu Fund Venture GroupOrphinic Scientific Sa

Description

Vasa Therapeutics, Inc. ("Vasa"), a preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, announced today the closing of series seed funding led by Orphinic Scientific SA ("Orphinic"), an early-stage investor focused on companies with game-changing potential. The round also included participation from private investments funds NuFund Venture Group, SeedFolio, and others.

Company Information

Company

Vasa Therapeutics

Location

Encinitas, California, United States

About

Vasa Therapeutics is a San Diego-based, private biotechnology company committed to the discovery and development of therapeutics that target pathophysiology of cardiovascular aging. Vasa Therapeutics has three active preclinical programs: 1. VS-041 is the first personalized medicine-based treatment of HFpEF. VS-041 shows robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. Phase 1 clinical trial of VS-041 is planned for 2024. 2. Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease. 3. A best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns